Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 32Thoracic 2Sarcoma 2Gynecologic 2Gastrointestinal 2Dermatologic 2NET 1Lymphoid 1Head & Neck 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 148Carcinoma, Neuroendocrine 57Thyroid Cancer, Papillary 54Pheochromocytoma 52Thyroid Neoplasms 42Paraganglioma 42Pituitary Neoplasms 39Neoplasms 32Adrenocortical Carcinoma 31Multiple Endocrine Neoplasia Type 1 29Gastro-enteropancreatic neuroendocrine tumor 29Thyroid Carcinoma, Anaplastic 24Lung Neoplasms 22Small Cell Lung Carcinoma 21Sarcoma 20Carcinoid Tumor 20Breast Neoplasms 19Neoplasm Metastasis 18Carcinoma, Non-Small-Cell Lung 18Adenoma, Islet Cell 18Melanoma 17Carcinoma, Hepatocellular 17Pancreatic Neoplasms 16Colorectal Neoplasms 16Adrenal Gland Neoplasms 16Prostatic Neoplasms 15Ovarian Neoplasms 15Neuroblastoma 15Carcinoma, Renal Cell 15Adenocarcinoma, Follicular 15

Interventions

cabozantinib 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Clear-cell metastatic renal cell carcinoma × Endocrine × 1 year × Clear all
NCT05263050 2026-05-22

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Fox Chase Cancer Center

Phase 2 Recruiting
111 enrolled
EndocrineGenitourinaryNET

Clear-cell metastatic renal cell carcinoma, Carcinoid Tumor, Carcinoma, Renal Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡